These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37676822)

  • 1. Biologic disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts.
    Möller B; Scholz GA; Amsler J; Ciurea A; Micheroli R; Nissen MJ; Papagiannoulis E; Blapp C; Scherer A; Yawalkar N
    Rheumatology (Oxford); 2024 May; 63(6):1528-1533. PubMed ID: 37676822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
    Pontifex EK; Dissanayake K; Bursill D; Gill T
    Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
    Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
    Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting.
    Navarini L; Costa L; Tasso M; Chimenti MS; Currado D; Fonti GL; Ciccozzi M; Margiotta DPE; Benigno C; De Martino E; Perricone R; Afeltra A; Scarpa R; Caso F
    Clin Rheumatol; 2020 Sep; 39(9):2663-2670. PubMed ID: 32189149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network.
    Gladman DD; Choquette D; Khraishi M; Inman RD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):641-648. PubMed ID: 36521913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
    Gabay C; Riek M; Scherer A; Finckh A;
    Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
    Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
    Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
    Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
    Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs.
    Keskin Y; Nas K; Kiliç E; Sargin B; Acer Kasman S; Alkan H; Şahin N; Cengiz G; Cuzdan N; Albayrak Gezer İ; Keskin D; Mülkoğlu C; Resorlu H; Ataman Ş; Bal A; Duruoz MT; Küçükakkas O; Yurdakul OV; Alkan Melikoğlu M; Aydin Y; Ayhan FF; Bodur H; Çaliş M; Çapkin E; Devrimsel G; Gök K; Hizmetli S; Kamanli A; Ecesoy H; Kutluk Ö; Şen N; Şendur ÖF; Tekeoğlu İ; Tolu S; Toprak M; Tuncer T
    Arch Rheumatol; 2021 Mar; 36(1):1-9. PubMed ID: 34046563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
    Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
    Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
    PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching biologics in the treatment of psoriatic arthritis.
    Merola JF; Lockshin B; Mody EA
    Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA.
    Santos H; Eusébio M; Borges J; Gonçalves D; Ávila-Ribeiro P; Faria DS; Lopes C; Rovisco J; Águeda A; Nero P; Valente P; Cravo AR; Santos MJ
    Acta Reumatol Port; 2017; 42(4):287-299. PubMed ID: 29342473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Ruyssen-Witrand A; Perry R; Watkins C; Braileanu G; Kumar G; Kiri S; Nott D; Liu-Leage S; Hartz S; Sapin C
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment.
    Janta I; Martínez-Estupiñán L; Valor L; Montoro M; Baniandres Rodriguez O; Hernández Aragüés I; Bello N; Hernández-Flórez D; Hinojosa M; Martínez-Barrio J; Nieto-González JC; Ovalles-Bonilla JG; González CM; López-Longo FJ; Monteagudo I; Naredo E; Carreño L
    Clin Rheumatol; 2015 May; 34(5):935-42. PubMed ID: 25636779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.